COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02251275




Registration number
NCT02251275
Ethics application status
Date submitted
25/09/2014
Date registered
29/09/2014
Date last updated
27/11/2019

Titles & IDs
Public title
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
Scientific title
A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Immediate-release Tolvaptan (OPC-41061, 30 mg to 120 mg/Day, Split Dose) in Subjects With Autosomal Dominant Polycystic Kidney Disease
Secondary ID [1] 0 0
156-13-211
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Polycystic Kidney, Autosomal Dominant 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Renal and Urogenital 0 0 0 0
Kidney disease
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Tolvaptan

Experimental: Tolvaptan - Tolvaptan was self-administered orally as split-dose regimens. The dose regimens used in this trial were 15/15 milligram (mg), 30/15 mg, 45/15 mg, 60/30 mg, or 90/30 mg. Starting doses were dependent upon the participant's previous trial as follows:
Trial 156-13-210: initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability.
Trial 156-08-271: retained the last dose level of tolvaptan received in the trial (45/15 mg, 60/30 mg, or 90/30 mg) and started at that same dose in Trial 156-13-211.
Other Trials (156-04-251 and 156-09-290): initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability.


Treatment: Drugs: Tolvaptan
Tolvaptan tablets (15 or 30 mg) self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) - An adverse event (AE) was as any untoward medical occurrence associated with the use of an investigational medicinal product (IMP), whether or not considered IMP related. A TEAE was an AE that started after trial drug treatment; or if the event was continuous from baseline and was serious, related to IMP, or resulted in death, discontinuation, interruption or reduction of trial therapy. A serious TEAE included any event that resulted in: death, life-threatening, persistent or significant incapacity, substantial disruption of ability to conduct normal life functions, required inpatient hospitalization, prolonged hospitalization, congenital anomaly/birth defect, or other medically significant events as per medical judgment, that jeopardized the participant and that required medical or surgical intervention. A severe TEAE was an inability to work or perform normal daily activity. A summary of serious and all other non-serious TEAEs, regardless of causality, is located in the AE section.
Timepoint [1] 0 0
Baseline through end of treatment (up to 42 months) and follow-up 7 days posttreatment(+ 7 days)

Eligibility
Key inclusion criteria
- Male and female participants = 18 years with confirmed diagnosis of ADPKD (during
participation in prior tolvaptan trials) who have completed and transferred from the
double-blind Trial 156-13-210 (12-month period including post treatment follow-up,
regardless of whether this was on-treatment or off-treatment), or completed Trial
156-08-271 or a prior tolvaptan trial, or interrupted or discontinued treatment in a
prior tolvaptan ADPKD trial other than Trial 156-13-210. Participants may be enrolled
with the medical monitor approval, and additional close monitoring may be required at
the beginning of the trial.

- eGFR = 20 milliliter (mL)/minute (min)/1.73 meter squared (m^2) within 3 months prior
to the baseline visit. Participants who have an eGFR = 20 mL/min/1.73 m^2 may be
enrolled with medical monitor approval.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Need for chronic diuretic use

- Hepatic impairment based on liver function abnormalities other than that expected for
ADPKD with cystic liver disease

- Women of childbearing potential who do not agree to practice 2 different methods of
birth control or remain abstinent during the trial and for 30 days after the last dose
of investigational medicinal product (IMP)

- Women who are breast-feeding and/or who have a positive pregnancy test result prior to
receiving IMP.

- Participants with contraindications to required trial assessments (contraindications
to optional assessments, for example, magnetic resonance imaging [MRI] are not a
limitation).

- Participants who in the opinion of the investigator or the medical monitor, have a
medical history or medical finding inconsistent with safety or trial compliance

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Recruitment hospital [1] 0 0
- Camperdown
Recruitment hospital [2] 0 0
- New Lambton Heights
Recruitment hospital [3] 0 0
- St Leonards
Recruitment hospital [4] 0 0
- Westmead
Recruitment hospital [5] 0 0
- Woolloongabba
Recruitment hospital [6] 0 0
- Adelaide
Recruitment hospital [7] 0 0
- Launceston
Recruitment hospital [8] 0 0
- Parkville
Recruitment hospital [9] 0 0
- Reservoir
Recruitment hospital [10] 0 0
- Richmond
Recruitment hospital [11] 0 0
- Perth
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [3] 0 0
2065 - St Leonards
Recruitment postcode(s) [4] 0 0
2145 - Westmead
Recruitment postcode(s) [5] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [6] 0 0
5000 - Adelaide
Recruitment postcode(s) [7] 0 0
7250 - Launceston
Recruitment postcode(s) [8] 0 0
3050 - Parkville
Recruitment postcode(s) [9] 0 0
3073 - Reservoir
Recruitment postcode(s) [10] 0 0
3121 - Richmond
Recruitment postcode(s) [11] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Idaho
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Minnesota
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
Nevada
Country [18] 0 0
United States of America
State/province [18] 0 0
New Jersey
Country [19] 0 0
United States of America
State/province [19] 0 0
New York
Country [20] 0 0
United States of America
State/province [20] 0 0
North Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
North Dakota
Country [22] 0 0
United States of America
State/province [22] 0 0
Ohio
Country [23] 0 0
United States of America
State/province [23] 0 0
Oregon
Country [24] 0 0
United States of America
State/province [24] 0 0
Pennsylvania
Country [25] 0 0
United States of America
State/province [25] 0 0
South Carolina
Country [26] 0 0
United States of America
State/province [26] 0 0
Tennessee
Country [27] 0 0
United States of America
State/province [27] 0 0
Texas
Country [28] 0 0
United States of America
State/province [28] 0 0
Vermont
Country [29] 0 0
United States of America
State/province [29] 0 0
Virginia
Country [30] 0 0
United States of America
State/province [30] 0 0
Washington
Country [31] 0 0
United States of America
State/province [31] 0 0
West Virginia
Country [32] 0 0
Argentina
State/province [32] 0 0
Buenos Aires
Country [33] 0 0
Argentina
State/province [33] 0 0
Córdoba
Country [34] 0 0
Belgium
State/province [34] 0 0
Aalst
Country [35] 0 0
Belgium
State/province [35] 0 0
Bruxelles
Country [36] 0 0
Belgium
State/province [36] 0 0
Edegem
Country [37] 0 0
Belgium
State/province [37] 0 0
Gent
Country [38] 0 0
Belgium
State/province [38] 0 0
Kortrijk
Country [39] 0 0
Belgium
State/province [39] 0 0
Leuven
Country [40] 0 0
Belgium
State/province [40] 0 0
Liège
Country [41] 0 0
Canada
State/province [41] 0 0
Alberta
Country [42] 0 0
Canada
State/province [42] 0 0
Newfoundland and Labrador
Country [43] 0 0
Canada
State/province [43] 0 0
Ontario
Country [44] 0 0
Canada
State/province [44] 0 0
Quebec
Country [45] 0 0
Czechia
State/province [45] 0 0
Brno
Country [46] 0 0
Czechia
State/province [46] 0 0
Ceske Budejovice
Country [47] 0 0
Czechia
State/province [47] 0 0
Hradec Kralove
Country [48] 0 0
Czechia
State/province [48] 0 0
Jihlava
Country [49] 0 0
Czechia
State/province [49] 0 0
Jilemnice
Country [50] 0 0
Czechia
State/province [50] 0 0
Liberec
Country [51] 0 0
Czechia
State/province [51] 0 0
Ostrava
Country [52] 0 0
Czechia
State/province [52] 0 0
Praha 2
Country [53] 0 0
Czechia
State/province [53] 0 0
Praha 4
Country [54] 0 0
Denmark
State/province [54] 0 0
Aalborg
Country [55] 0 0
Denmark
State/province [55] 0 0
Aarhus N
Country [56] 0 0
Denmark
State/province [56] 0 0
Holstebro
Country [57] 0 0
Germany
State/province [57] 0 0
Baden Wuerttemberg
Country [58] 0 0
Germany
State/province [58] 0 0
Bayern
Country [59] 0 0
Germany
State/province [59] 0 0
Hessen
Country [60] 0 0
Germany
State/province [60] 0 0
Nordrhein Westfalen
Country [61] 0 0
Germany
State/province [61] 0 0
Sachsen
Country [62] 0 0
Germany
State/province [62] 0 0
Berlin
Country [63] 0 0
Hungary
State/province [63] 0 0
Budapest
Country [64] 0 0
Hungary
State/province [64] 0 0
Pecs
Country [65] 0 0
Hungary
State/province [65] 0 0
Szeged
Country [66] 0 0
Israel
State/province [66] 0 0
Ashkelon
Country [67] 0 0
Israel
State/province [67] 0 0
Jerusalem
Country [68] 0 0
Israel
State/province [68] 0 0
Nahariya
Country [69] 0 0
Israel
State/province [69] 0 0
Petach Tikva
Country [70] 0 0
Israel
State/province [70] 0 0
Ramat-Gan
Country [71] 0 0
Israel
State/province [71] 0 0
Tel Aviv
Country [72] 0 0
Italy
State/province [72] 0 0
Brescia
Country [73] 0 0
Italy
State/province [73] 0 0
Bari
Country [74] 0 0
Italy
State/province [74] 0 0
Lecco
Country [75] 0 0
Italy
State/province [75] 0 0
Milano
Country [76] 0 0
Italy
State/province [76] 0 0
Modena
Country [77] 0 0
Italy
State/province [77] 0 0
Napoli
Country [78] 0 0
Italy
State/province [78] 0 0
Pavia
Country [79] 0 0
Netherlands
State/province [79] 0 0
Amsterdam
Country [80] 0 0
Netherlands
State/province [80] 0 0
Groningen
Country [81] 0 0
Netherlands
State/province [81] 0 0
Nijmegen
Country [82] 0 0
Norway
State/province [82] 0 0
Bergen
Country [83] 0 0
Poland
State/province [83] 0 0
Ciechanow
Country [84] 0 0
Poland
State/province [84] 0 0
Gdansk
Country [85] 0 0
Poland
State/province [85] 0 0
Golub Dobrzyn
Country [86] 0 0
Poland
State/province [86] 0 0
Krakow
Country [87] 0 0
Poland
State/province [87] 0 0
Lodz
Country [88] 0 0
Poland
State/province [88] 0 0
Lublin
Country [89] 0 0
Poland
State/province [89] 0 0
Szczecin
Country [90] 0 0
Poland
State/province [90] 0 0
Warszawa
Country [91] 0 0
Poland
State/province [91] 0 0
Wroclaw
Country [92] 0 0
Romania
State/province [92] 0 0
Bucuresti
Country [93] 0 0
Romania
State/province [93] 0 0
Oradea
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Kemerovo
Country [95] 0 0
Russian Federation
State/province [95] 0 0
Krasnoyarsk
Country [96] 0 0
Russian Federation
State/province [96] 0 0
Saint-Petersburg
Country [97] 0 0
Russian Federation
State/province [97] 0 0
Yaroslavl
Country [98] 0 0
South Africa
State/province [98] 0 0
Gauteng
Country [99] 0 0
South Africa
State/province [99] 0 0
KwaZulu-Natal
Country [100] 0 0
South Africa
State/province [100] 0 0
Western Cape
Country [101] 0 0
Spain
State/province [101] 0 0
Barcelona
Country [102] 0 0
Spain
State/province [102] 0 0
Ciudad Real
Country [103] 0 0
Spain
State/province [103] 0 0
Madrid
Country [104] 0 0
Spain
State/province [104] 0 0
Valencia
Country [105] 0 0
Sweden
State/province [105] 0 0
Göteborg
Country [106] 0 0
Sweden
State/province [106] 0 0
Linköping
Country [107] 0 0
Sweden
State/province [107] 0 0
Stockholm
Country [108] 0 0
Sweden
State/province [108] 0 0
Uppsala
Country [109] 0 0
United Kingdom
State/province [109] 0 0
County Antrim
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Devon
Country [111] 0 0
United Kingdom
State/province [111] 0 0
East Riding Of Yorkshire
Country [112] 0 0
United Kingdom
State/province [112] 0 0
East Sussex
Country [113] 0 0
United Kingdom
State/province [113] 0 0
Greater London
Country [114] 0 0
United Kingdom
State/province [114] 0 0
Greater Manchester
Country [115] 0 0
United Kingdom
State/province [115] 0 0
Hertfordshire
Country [116] 0 0
United Kingdom
State/province [116] 0 0
Highland Region
Country [117] 0 0
United Kingdom
State/province [117] 0 0
Leicestershire
Country [118] 0 0
United Kingdom
State/province [118] 0 0
Lothian Region
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Norfolk
Country [120] 0 0
United Kingdom
State/province [120] 0 0
South Yorkshire
Country [121] 0 0
United Kingdom
State/province [121] 0 0
Staffordshire
Country [122] 0 0
United Kingdom
State/province [122] 0 0
Tyne & Wear
Country [123] 0 0
United Kingdom
State/province [123] 0 0
Warwickshire
Country [124] 0 0
United Kingdom
State/province [124] 0 0
West Midlands
Country [125] 0 0
United Kingdom
State/province [125] 0 0
Middlesbrough
Country [126] 0 0
United Kingdom
State/province [126] 0 0
Swansea

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Otsuka Pharmaceutical Development & Commercialization, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the trial was to evaluate and describe the long term safety of tolvaptan in
participants with autosomal dominant polycystic kidney disease (ADPKD).
Trial website
https://clinicaltrials.gov/show/NCT02251275
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications